NRx Pharmaceuticals

Company Overview

Snapshot

Founded in October 2014 by Daniel C. Javitt and Jonathan C. Javitt, NRx Pharmaceuticals operates with 11–50 employees. The company has raised a total of $176.18 million across 7 funding rounds from 1 investor. NRx Pharmaceuticals became public on NASDAQ in May 2021.

Business overview

NRx Pharmaceuticals is a specialized biopharmaceutical company focused on developing medicines for life-threatening Central Nervous System (CNS) diseases, specifically severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company's pipeline leverages a proprietary, dual-targeted mechanism of action that modulates NMDA and 5HT2A receptors. NRx Pharmaceuticals operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development, aiming to serve patients and providers in the healthcare industry.

Strategic signal

In September 2025, NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, completed the acquisition of Dura Medical, marking an initial step in establishing a network of interventional psychiatry clinics. This strategic move signals NRx Pharmaceuticals' expansion beyond drug development into direct patient care infrastructure, indicating a broader strategy to integrate its therapeutic solutions with clinical delivery and potentially accelerate market penetration for its CNS treatments.

Company Intelligence Q&A

What was a significant recent regulatory achievement for NRx Pharmaceuticals?

In September 2025, NRx Pharmaceuticals secured FDA Fast Track designation for its IV Ketamine Formulation NRX-100, intended for suicidal depression. This was followed by the FDA's approval of a suitability petition for NRx's proposed strength of preservative-free ketamine later that month.

What is the latest development regarding NRx Pharmaceuticals' ketamine-based therapies?

In October 2025, NRx Pharmaceuticals announced it is advancing a two-pronged approach to bring innovative therapies to market, strengthening its pipeline with dual pathways for ketamine-based treatments.

What was a key strategic acquisition by NRx Pharmaceuticals' subsidiary?

In September 2025, HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, completed the acquisition of Dura Medical. This acquisition represents an initial step in building a network of interventional psychiatry clinics.

When did NRx Pharmaceuticals become a publicly traded company?

NRx Pharmaceuticals became public on NASDAQ in May 2021 through a SPAC merger with Big Rock Partners Acquisition Corporation.

What was a recent financial activity for NRx Pharmaceuticals?

In August 2024, NRx Pharmaceuticals announced up to $16 million in senior secured debt financing from Anson Funds.